Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Blood (2024) 144 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2024-200936

Published: 2024

Journal Articles

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Neha Dixit, Binhuan Wang, Kevin Zhao, Catherine Thieblemont, Irit Avivi Mazza, David Lavie, Abraham Avigdor, Carlos Grande Garcia, Andrew J. Steele, Mostafa Seliem, Pegah Jafarinasabian, Edith Szafer Glusman

Blood (2024) 144 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2024-200395

Published: 2024

Journal Articles

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Tycel J. Phillips, Michael Roost Clausen, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Y Cheah, Jieying Jiang, Kubra Karagoz, Mohammad Atiya, Christian Eskelund, Han Si, Edith Szafer Glusman, Andrew J. Steele, Charles Kearns, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2024-199799

Published: 2024

Journal Articles

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3233.

https://doi.org/10.1182/blood-2024-199916

Published: 2024

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL)

PK Epling-Burnette, Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt - van den Heuvel, Apurvasena Parikh, Tommy Li, Christopher W Chiu, Adam Chervin, Edward B Reilly, Edith Szafer-Glusman

Blood (2022) 140 (Supplement 1): 9283–9285.

https://doi.org/10.1182/blood-2022-162538

Published: 2022

Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood (2022) 139 (22): 3278–3289.

https://doi.org/10.1182/blood.2021014488

Published: 2022

Includes: Supplemental data

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Shih-Shih Chen, Jacqueline Barrientos, Xiao-Jie Yan, Uwe Wirtz, Edith Szafer-Glusman, Kanti R Rai, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2021-153685

Published: 2021

Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Blood (2020) 136 (23): 2628–2637.

https://doi.org/10.1182/blood.2020005588

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134446

Published: 2020

Journal Articles

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Constantine S. Tam, MD, Radhakrishnan Ramchandren, MD, Robert Chen, MD, Lionel Karlin, MD, Geoffrey Chong, MD, Wojciech Jurczak, MD PhD, Ka Lung Wu, MD PhD, Mark Bishton, MBChB, MRCP, FRCPath, PhD, Graham P. Collins, MD DPhil, Paul Eliadis, MBBS, FRACP, FRCPA, Frédéric Peyrade, MD, Edith Szafer-Glusman, PhD, Yihua Lee, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 39–41.

https://doi.org/10.1182/blood-2020-134392

Published: 2020

Journal Articles

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Blood (2019) 133 (18): 1964–1976.

https://doi.org/10.1182/blood-2018-11-880526

Published: 2019

Includes: Supplemental data

Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny

Blood (2019) 133 (9): 919–926.

https://doi.org/10.1182/blood-2018-07-862862

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Blood (2018) 132 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2018-99-116806

Published: 2018

Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Blood (2018) 132 (Supplement 1): 782.

https://doi.org/10.1182/blood-2018-99-118519

Published: 2018

Journal Articles

BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL

Edith Szafer-Glusman, Franklin V. Peale, Jr., Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, MD, Elizabeth Punnoose

Blood (2017) 130 (Supplement 1): 418.

https://doi.org/10.1182/blood.V130.Suppl_1.418.418

Published: 2017

Journal Articles

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Edith Szafer-Glusman, Juan Liu, Franklin V. Peale, Jr., Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, MDMPH, Günter Fingerle-Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth Punnoose

Blood (2017) 130 (Supplement 1): 419.

https://doi.org/10.1182/blood.V130.Suppl_1.419.419

Published: 2017

Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser

Blood (2016) 128 (22): 3032.

https://doi.org/10.1182/blood.V128.22.3032.3032

Published: 2016

NARROW

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL)

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only